|
Apr 24, 2024
|
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
|
|
|
Mar 04, 2024
|
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
|
|
|
Feb 29, 2024
|
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
|
|